134 related articles for article (PubMed ID: 18251569)
21. Regional specificity of 1p/19q co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients.
Wang K; Wang Y; Fan X; Li Y; Liu X; Wang J; Ai L; Dai J; Jiang T
J Neurooncol; 2018 Feb; 136(3):523-531. PubMed ID: 29230668
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and management of oligodendroglioma.
van den Bent MJ
Semin Oncol; 2004 Oct; 31(5):645-52. PubMed ID: 15497117
[TBL] [Abstract][Full Text] [Related]
23. Oligodendroglial tumors: diagnostic and molecular pathology.
Rodriguez FJ; Giannini C
Semin Diagn Pathol; 2010 May; 27(2):136-45. PubMed ID: 20860317
[TBL] [Abstract][Full Text] [Related]
24. Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors.
Fujisawa H; Marukawa K; Hasegawa M; Tohma Y; Hayashi Y; Uchiyama N; Tachibana O; Yamashita J
J Neurosurg; 2002 Dec; 97(6):1350-5. PubMed ID: 12507133
[TBL] [Abstract][Full Text] [Related]
25. Oligodendroglioma with neurocytic differentiation and characteristic loss of heterozygosity on chromosomes 1p and 19q.
Vajtai I; Arnold M; Vassella E
Acta Neuropathol; 2005 Nov; 110(5):520-2. PubMed ID: 16222523
[No Abstract] [Full Text] [Related]
26. Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors.
Srebotnik-Kirbiš I; Limbäck-Stokin C
J Neurooncol; 2016 Sep; 129(3):415-422. PubMed ID: 27406587
[TBL] [Abstract][Full Text] [Related]
27. Tumour-to-tumour metastasis from papillary thyroid carcinoma with BRAF mutation to lung adenocarcinoma with EGFR mutation: the utility of mutation-specific antibodies.
Katsuya Y; Yoshida A; Watanabe S; Tsuta K
Histopathology; 2015 Aug; 67(2):262-6. PubMed ID: 25556681
[TBL] [Abstract][Full Text] [Related]
28. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
29. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
Sathornsumetee S; Cheunsuchon P; Sangruchi T
World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
[TBL] [Abstract][Full Text] [Related]
30. Oligodendroglioma showing pleomorphic xanthoastrocytoma-like perivascular microlesion: With IDH1, TERT promoter mutation and 1p/19q codeletion detected in both components.
Murakami C; Ikota H; Nobusawa S; Nakata S; Yamazaki T; Hashiba Y; Hirato J; Yokoo H
Pathol Int; 2020 Jan; 70(1):40-46. PubMed ID: 31855307
[TBL] [Abstract][Full Text] [Related]
31. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
32. Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology.
Nutt CL
Neurosurg Focus; 2005 Nov; 19(5):E2. PubMed ID: 16398466
[TBL] [Abstract][Full Text] [Related]
33. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
Kros JM; Gorlia T; Kouwenhoven MC; Zheng PP; Collins VP; Figarella-Branger D; Giangaspero F; Giannini C; Mokhtari K; Mørk SJ; Paetau A; Reifenberger G; van den Bent MJ
J Neuropathol Exp Neurol; 2007 Jun; 66(6):545-51. PubMed ID: 17549014
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany.
Eszlinger M; Böhme K; Ullmann M; Görke F; Siebolts U; Neumann A; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Ruschenburg I; Paschke R
Thyroid; 2017 Mar; 27(3):402-411. PubMed ID: 28071986
[TBL] [Abstract][Full Text] [Related]
35. [IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma].
Ji YC; Zhan YB; Liu XZ; Zhang ZY
Zhonghua Yi Xue Za Zhi; 2019 Jul; 99(25):1959-1962. PubMed ID: 31269600
[No Abstract] [Full Text] [Related]
36. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
[TBL] [Abstract][Full Text] [Related]
37. [Significance and prospects of study on molecular alterations in oligodendrogliomas].
Gresner SM; Liberski PP
Neurol Neurochir Pol; 2007; 41(4):333-9. PubMed ID: 17874342
[TBL] [Abstract][Full Text] [Related]
38. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
Cahill DP; Louis DN; Cairncross JG
CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of 1p/19q chromosomal codeletion in patients with oligodendroglioma.
Laghari AA; Khalid MU; Qadeer N; Shamim MS
J Pak Med Assoc; 2019 Jan; 69(1):132-134. PubMed ID: 30623930
[TBL] [Abstract][Full Text] [Related]
40. Detection of allelic status of 1p and 19q by microsatellite-based PCR versus FISH: limitations and advantages in application to patient management.
Jha P; Sarkar C; Pathak P; Sharma MC; Kale SS; Gupta D; Chosdol K; Suri V
Diagn Mol Pathol; 2011 Mar; 20(1):40-7. PubMed ID: 21326038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
